 Connection
David Kao to Propanolamines
This is a "connection" page, showing publications David Kao has written about Propanolamines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.043 |
|
|
|
-
Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar; 15(3):324-33.
Score: 0.437
-
Kao DP, Wagner BD, Robertson AD, Bristow MR, Lowes BD. A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PLoS One. 2012; 7(11):e48184.
Score: 0.435
-
Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradovic V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ. Bucindolol for the Maintenance of Sinus?Rhythm in a Genotype-Defined HF?Population: The GENETIC-AF Trial. JACC Heart Fail. 2019 07; 7(7):586-598.
Score: 0.170
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|